Table 1.
Demographic, ophthalmic, tumor and treatment characteristics with proportions of patients experiencing local tumor recurrence and enucleation among the cohort studied
| Local tumor recurrence |
Enucleation | |||||||
|---|---|---|---|---|---|---|---|---|
| N | Yes | No | Yes | No | ||||
| Demographic characteristics | ||||||||
| Gender | ||||||||
| Male | 14 | 50% | 9 | 5 | 64.3% | 3 | 11 | 21% |
| Female | 14 | 50% | 4 | 10 | 28.6% | 1 | 13 | 7% |
| Age (years) | ||||||||
| <50 | 5 | 18% | 3 | 2 | 60.0% | 1 | 4 | 20% |
| 50–69 | 14 | 50% | 7 | 7 | 50.0% | 3 | 11 | 21% |
| ≥70 | 9 | 32% | 3 | 6 | 33.3% | 0 | 9 | 0% |
| Ophthalmic characteristics | ||||||||
| Visual acuity in eye with tumor | ||||||||
| ≥20/20 | 1 | 4% | 0 | 1 | 0.0% | 0 | 1 | 0% |
| 20/25–20/40 | 19 | 68% | 8 | 11 | 42.1% | 1 | 18 | 5% |
| 20/50–20/160 | 5 | 18% | 2 | 3 | 40.0% | 1 | 4 | 20% |
| ≤20/200 | 3 | 11% | 3 | 0 | 100.0% | 2 | 1 | 67% |
| Visual acuity in fellow eye | ||||||||
| ≥20/20 | 2 | 7% | 1 | 1 | 50.0% | 0 | 2 | 0% |
| 20/25–20/40 | 25 | 89% | 11 | 14 | 44.0% | 3 | 22 | 12% |
| 20/50–20/160 | 1 | 4% | 1 | 0 | 100.0% | 1 | 0 | 100% |
| ≤20/200 | 0 | 0% | 0 | 0 | 0 | 0 | ||
| Tumor characteristics | ||||||||
| Tumor apical height (mm) | ||||||||
| <2.5 | 11 | 39% | 6 | 5 | 54.5% | 1 | 10 | 9% |
| 2.5–5.0 | 17 | 61% | 7 | 10 | 41.2% | 3 | 14 | 18% |
| Longest basal dimension (mm) | ||||||||
| <4.5 | 0 | 0% | 0 | 0 | 0.0% | 0 | 0 | 0% |
| 4.5–8.0 | 5 | 18% | 3 | 2 | 60.0% | 1 | 4 | 20% |
| 8.1–11.0 | 14 | 50% | 7 | 12 | 36.8% | 2 | 17 | 11% |
| 11.1–14.0 | 4 | 14% | 3 | 1 | 75.0% | 1 | 3 | 25% |
| Distance to proximal edge of optic disc (mm) | ||||||||
| <2 | 1 | 4% | 1 | 0 | 100.0% | 0 | 1 | 0% |
| 2.1–4.0 | 7 | 25% | 5 | 2 | 71.4% | 3 | 4 | 43% |
| 4.1–6.0 | 7 | 25% | 5 | 2 | 71.4% | 0 | 7 | 0% |
| 6.1–8.0 | 4 | 14% | 1 | 3 | 25.0% | 1 | 3 | 25% |
| >8 | 9 | 32% | 1 | 8 | 11.1% | 0 | 9 | 0% |
| Distance to center of foveal avascular zone (mm) | ||||||||
| 0 | 4 | 14% | 4 | 0 | 100.0% | 2 | 2 | 50% |
| 0.1–2.0 | 4 | 14% | 2 | 2 | 50.0% | 1 | 3 | 25% |
| 2.1–5.0 | 3 | 11% | 3 | 0 | 100.0% | 1 | 2 | 33% |
| 5.1–8.0 | 6 | 21% | 3 | 3 | 50.0% | 0 | 6 | 0% |
| >8.0 | 1 | 39% | 1 | 10 | 9.1% | 0 | 11 | 0% |
| 1 | ||||||||
| Location of anterior tumor border | ||||||||
| Ciliary body | 4 | 14% | 0 | 4 | 0.0% | 0 | 4 | 0% |
| Equator to ora serrata | 1 | 36% | 3 | 7 | 30.0% | 0 | 10 | 0% |
| 0 | ||||||||
| Posterior to equator | 1 | 50% | 10 | 4 | 71.4% | 4 | 10 | 29% |
| 4 | ||||||||
| Location of posterior tumor border | ||||||||
| Equator to ora serrata | 1 | 4% | 0 | 1 | 0.0% | 0 | 1 | 0% |
| Posterior to equator | 2 | 96% | 13 | 14 | 48.1% | 4 | 23 | 15% |
| 7 | ||||||||
| Retina detached over tumor | ||||||||
| No | 2 | 82% | 9 | 14 | 39.1% | 2 | 21 | 9% |
| 3 | ||||||||
| Yes | 5 | 18% | 4 | 1 | 80.0% | 2 | 3 | 40% |
| Tumor shape | ||||||||
| Dome | 2 | 89% | 11 | 14 | 44.0% | 4 | 21 | 16% |
| 5 | ||||||||
| Collar button | 1 | 4% | 1 | 0 | 100.0% | 0 | 1 | 0% |
| Placoid | 2 | 7% | 1 | 1 | 50.0% | 0 | 2 | 0% |
| Treatment characteristics | ||||||||
| Delivered dose at tumor apex (Gy) | ||||||||
| 65.0–80.0 | 1 | 68% | 7 | 12 | 36.8% | 2 | 17 | 11% |
| 9 | ||||||||
| 80.1–85.0 | 7 | 25% | 5 | 2 | 71.4% | 1 | 6 | 14% |
| 85.1–90.0 | 2 | 7% | 1 | 1 | 50.0% | 1 | 1 | 50% |
| Delivered dose to sclera (Gy) | ||||||||
| <293.0 | 2 | 79% | 11 | 11 | 50.0% | 2 | 20 | 9% |
| 2 | ||||||||
| 293.0–342.9 | 2 | 7% | 1 | 1 | 50.0% | 1 | 1 | 50% |
| 343.0–409.9 | 4 | 14% | 1 | 3 | 25.0% | 1 | 3 | 25% |
| ≥410 | 0 | 0% | 0 | 0 | 0.0% | 0 | 0 | 0% |
| Plaque model (physical diameter, active diameter in mm) | ||||||||
| CCX (11.6, 9.5) | 1 | 4% | 1 | 0 | 100.0% | 0 | 1 | 0% |
| CCA (15.3, 13.0) | 2 | 79% | 12 | 10 | 54.5% | 4 | 18 | 18% |
| 2 | ||||||||
| CIA (15.3, 13.0) | 3 | 11% | 0 | 3 | 0.0% | 0 | 3 | 0% |
| CIB (20.2, 17.8) | 2 | 7% | 0 | 2 | 0.0% | 0 | 2 | 0% |
| Plaque serial number | ||||||||
| CCX-104 | 1 | 4% | 1 | 0 | 100.0% | 0 | 1 | 0% |
| CCA-571 | 9 | 32% | 5 | 4 | 55.6% | 1 | 8 | 11% |
| CCA-992 | 1 | 39% | 5 | 6 | 45.5% | 2 | 9 | 18% |
| 1 | ||||||||
| CCA-892 | 2 | 7% | 2 | 0 | 100.0% | 1 | 1 | 50% |
| CIA-173 | 2 | 7% | 0 | 2 | 0.0% | 0 | 2 | 0% |
| CIA-156 | 1 | 4% | 0 | 1 | 0.0% | 0 | 1 | 0% |
| CIB-307 | 2 | 7% | 0 | 2 | 0.0% | 0 | 2 | 0% |
| Difference in plaque diameter and tumor largest base diameter | ||||||||
| <6 mm | 1 | 57% | 10 | 6 | 62.5% | 3 | 13 | 19% |
| 6 | ||||||||
| ≥6 mm | 1 | 43% | 3 | 9 | 25.0% | 1 | 11 | 8% |
| 2 | ||||||||
| Adjuvant transpupillary thermotherapy | ||||||||
| Yes | 8 | 29% | 2 | 6 | 25.0% | 1 | 7 | 13% |
| No | 2 | 71% | 11 | 9 | 55.0% | 3 | 17 | 15% |
| 0 | ||||||||